Synthesis and antitumor mechanism investigation of iridium(III)/rhenium(I) complexes with 4-phenylimidazole ligands
Metallomics · 31.01.2026 · 18 (1)
DOI: 10.1093/mtomcs/mfag013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Metallomics, online erschienen am 27.03.2026. Verfasst von Lin-Yuan Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, P. R. China. Hauptthemen laut MEDLINE: Iridium, Antineoplastic Agents, Rhenium, Imidazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
In recent years, in addition to their potential diagnostic and therapeutic properties, the immunogenic cell death (ICD) induction activity of iridium(III) and rhenium(I) complexes has been extensively reported. 4-Phenylimidazole (4-PIM), as an indoleamine 2,3-dioxygenase (IDO) inhibitor, can improve the immunosuppressive environment and enhance the efficacy of chemotherapy drugs. In this study, a series of Ir(III)/Re(I)-PIM complexes [Ir-PIM-(1–3) and Re-PIM-(1–3)] by coordination 4-PIM with iridium(III)/rhenium(I) metal centers were designed and synthesized to study their antitumor mechanisms. Among the six complexes screened, four compounds Ir-PIM-(1–3) and Re-PIM-1 showed good antitumor activity against human triple negative breast cancer (MDA-MB-231) cells. And Ir-PIM-(1–3)/Re-PIM-1 exhibited potential IDO inhibitory activity, which can suppress the expression of IDO protein. Further mechanistic studies indicate that Ir-PIM-(1–3)/Re-PIM-1 can effectively enter MDA-MB-231 cells, and induce the depolarization of mitochondrial membrane potential, the elevation of reactive oxygen species, G2/M phase cell cycle arrest and the release of damage-related molecular patterns, exhibiting dual activity in inducing both apoptosis and ICD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, P. R. China.
ORCID-Profile: Rui-Rong Ye
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhu, L. Y., Jiang, C. R., Zhu, H., Yang, Y. S., Zhang, Z., Xu, M. T., Li, R. T., & Ye, R. R. (2026). Synthesis and antitumor mechanism investigation of iridium(III)/rhenium(I) complexes with 4-phenylimidazole ligands. Metallomics, 18(1). https://doi.org/10.1093/mtomcs/mfag013
Vancouver
Zhu LY, Jiang CR, Zhu H, Yang YS, Zhang Z, Xu MT, et al. Synthesis and antitumor mechanism investigation of iridium(III)/rhenium(I) complexes with 4-phenylimidazole ligands. Metallomics. 2026;18(1). doi:10.1093/mtomcs/mfag013
BibTeX
@article{Zhu2026,
author = {Zhu, Lin-Yuan and Jiang, Chun-Rong and Zhu, Hou and Yang, Yong-Sheng and Zhang, Zheng and Xu, Meng-Ting and Li, Rong-Tao and Ye, Rui-Rong},
title = {Synthesis and antitumor mechanism investigation of iridium(III)/rhenium(I) complexes with 4-phenylimidazole ligands},
journal = {Metallomics},
year = {2026},
volume = {18},
number = {1},
doi = {10.1093/mtomcs/mfag013}
}
EUVIMED